Cellectis Boosts IPO Target As Immunotherapy Cos. Rally
Cellectis SA boosted the target for its U.S. initial public offering to nearly $200 million Tuesday, increasing the number of American depositary shares it plans to sell as the France-listed company's...To view the full article, register now.
Already a subscriber? Click here to view full article